{"prompt": "['Target Volume Constraints and Compliance Criteria', 'Structure', 'Dosimetric', 'Per Protocol', 'Variation', 'Deviation', 'Parameter', 'Acceptable', 'Unacceptable', 'PTV', 'V100%[%]', '>=95', '>=94', '<94', 'PTV maximum', 'D0.03cc[%]', '<= 115', '>115-<=120', '> 120', 'dose', 'PTV minimum', 'D99%[%]', '>=95', '>=93- - < 95', '<93', 'dose', 'Per Protocol range is excluded from Variation Acceptable range.', 'Normal Structure Constraints and Compliance Criteria', 'The following normal tissue dose constraints represent the minimum level of acceptablibility for', 'protocol therapy. Whever possible, maximal sparing of normal tissues should be achieved to', 'minimize the risk of toxicity.', 'Normal Tissue Dose Constraints (ARM I, COPORT)', 'Structure', 'Dosimetric', 'Per Protocol', 'Variation Acceptable', 'Parameter', 'Rectum', 'V40 Gy[%]', '< 55', '<60', 'V65 Gy[%]', '<35', '< 39', 'Bladder', 'V40 Gy[%]', '<70', '< 77', 'V65 Gy[%', '<50', '< 55', 'Femoral Heads', 'V50 Gy[%]', '< 10', '< 11', 'Normal Tissue Dose Constraints (ARM II, HYPORT)', 'Structure', 'Dosimetric', 'Per Protocol', 'Variation Acceptable', 'Parameter', 'Rectum', 'V36 Gy[%]', '<55', '< 60', 'V59 Gy[%', '<35', '<39', 'Bladder', 'V35 Gy[%]', '<70', '<77', 'V57 Gy[%]', '<50', '<55', 'Femoral Heads', 'V44 Gy[%', '< 10', '< 11', 'Per Protocol range is excluded from Variation Acceptable range.', '5.2.8 Treatment Planning Priorities and Instructions', 'In order of priority, the following critical structure are listed in order of decreasing', 'importance. The following list is given as an example', 'NRG-GU003', '25', 'Version Date: April 26, 2019']['1. Rectum', '2. Bladder', '3. Femoral Heads', 'Dose matrix resolution', 'Dose grid size should be 3 mm in all directions.', '5.2.9', 'Patient specific QA', 'Any patient-specific QA that needs to be acquired should follow institutional guidelines.', 'For IMRT/VMAT plans, patient specific QA is highly recommended. QA is performed', 'by delivering the plan onto a phantom and measuring the dose using an ion chamber', 'array or other 2D/3D device. Measured dose distribution will be compared to planned', 'dose distribution using a Gamma criterion of 3% dose difference and 3 mm distance to', 'agreement. The pass rate should be at least 90% measured for the entire plan.', '5.2.10 Daily Treatment Localization/IGRT', 'Image-guided radiation therapy (IGRT) is radiation therapy using imaging to facilitate', 'accuracy and precision throughout its entire process from target and normal tissue', 'delineation, to radiation delivery, to adaptation of therapy to anatomic and biological', 'changes over time in individual patients. In this section we use the terminology IGRT', 'tofocus on image-guidance at the time of radiation delivery to ensure its adherence to the', 'planned treatment.', 'At the start of each fraction, patients should be initially positioned by laser alignment of skin', 'surface tattoos.', 'Daily IGRT is required. Fiducial marker placement is preferred but not required. Daily fiducial', 'based volumetric IGRT is ideal because fiducials aid in the interpretation by radiation therapists.', 'If fiducial markers are not present, volumetric IGRT based on soft-tissue alignment needs to be', 'performed. Finally, volumetric 3D IGRT is preferred because bladder and rectal filling can be', 'assessed for patient coaching purposes. Orthogonal 2D kV imaging requires fiducials.', 'Electromagnetic transponders or transabdominal ultrasound to identify the VUA may also be', 'used for daily IGRT.', 'Fiducial markers or electromagnetic transponders may be placed at the bilateral vesicourethral', 'anatamosis (VUA) and one in the retrovesicle (RV) space under sterile conditions with antibiotic', 'prophylaxis consistent with local practice standards. The three markers or electromagnetic', 'transponders should be identified and contoured on the simulation CT and designated right VUA,', 'left VUA, and RV according to their relative positions. The appropriate shifts should be made to', 'ensure daily registration of the markers or transponders with the position defined by the', 'treatment plan.', 'All image/signal-guidance data should be recorded and archived at the site and available for', 'review, if requested.', 'NRG-GU003', '26', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}